clinical trial · NCT06465108
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
HypoparathyroidismMBX 2109Placebo
brief summary
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
started
Aug 8, 2024
primary completion
May 23, 2025
completion
Jun 4, 2025
last updated
Mar 20, 2026
detailed description
This study is to investigate the safety, pharmacokinetics, and efficacy of MBX 2109 administered once weekly to patients with hypoparathyroidism. Given MBX 2109 is intended as a parathyroid hormone (PTH) replacement hormone to demonstrate that MBX 2109 can maintain serum calcium within a normal range without the need for active vitamin D and therapeutic calcium supplements.
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol